Research Updates
Avexitide Reaches Phase 3 Results in Post-Bariatric Hypoglycemia
Amylyx reported positive LUCIDITY results in August 2026. The study concerns GLP-1 receptor blockade after gastric bypass, a different use of the pathway.
Published by PeptideSchool Editorial Desk
Avexitide has a documented late-stage clinical program. On August 18, 2026, Amylyx reported positive topline results from LUCIDITY, its phase 3 trial in post-bariatric hypoglycemia following Roux-en-Y gastric bypass. The milestone is real; regulatory approval is a separate question.
Blocking the GLP-1 receptor
Avexitide is a GLP-1 receptor antagonist. Unlike a receptor agonist, which activates the receptor, an antagonist blocks its signaling. In this setting, the target is excessive insulin release associated with low blood glucose after bariatric surgery.
The earlier PREVENT phase 2 crossover trial enrolled 18 women. Compared with placebo, avexitide improved glucose nadirs during meal testing and reduced hypoglycemic episodes during the study. That peer-reviewed paper provides the clinical background for the later program. PREVENT trial.
What the phase 3 announcement adds
LUCIDITY enrolled 78 participants in a randomized, double-blind, placebo-controlled design. Amylyx reported a 55% reduction versus placebo in the composite rate of level 2 and level 3 hypoglycemic events, with a reported p value of 0.000003. The company also reported that the secondary endpoints were met. Sponsor program summary.
The dated SEC filing confirms the August 18 presentation of those results. It is a sponsor disclosure, not an independent regulatory judgment. Primary filing.
Keep the milestone in the right category
Topline results summarize a study before all the detail may be available in a complete journal article. Interpreting them requires attention to absolute event rates, adverse events, missing data, and the full analysis plan, not just the relative reduction.
The population also matters. This result concerns a defined complication after a particular bariatric procedure. It is not evidence for using avexitide as a general metabolic or weight-management peptide.
As of this review, Amylyx describes avexitide as investigational and plans an FDA application. The next milestones to track are the full phase 3 report and the regulatory submission and decision. A positive trial advances that process; it does not complete it.
References
PREVENT phase 2 avexitide trial
Sources
Educational content only. Not medical advice.